Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul T Martin

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Current Opinion in Pharmacology|June 18, 2003
Role of transcription factors in skeletal muscle and the potential for pharmacological manipulationPaul T Martin
Glycobiology|May 9, 2003
Dystroglycan glycosylation and its role in matrix binding in skeletal musclePaul T Martin
Current Molecular Medicine|June 23, 2007
Congenital muscular dystrophies involving the O-mannose pathwayPaul T Martin
Journal of Neurocytology|March 23, 2004
Glycobiology of the neuromuscular junctionPaul T Martin
Glycobiology|February 5, 2002
Glycobiology of the synapsePaul T Martin
Nature Clinical Practice. Neurology|August 26, 2006
Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stagePaul T Martin
Seminars in Pediatric Neurology|April 6, 2006
The dystroglycanopathies: the new disorders of O-linked glycosylationPaul T Martin
Methods in Enzymology|September 7, 2010
Genetic defects in muscular dystrophyKumaran Chandrasekharan, Paul T Martin
Molecular Therapy. Methods & Clinical Development|April 19, 2021
Micro-laminin gene therapy can function as an inhibitor of muscle disease in the dy<sup>W</sup> mouse model of MDC1ADavin Packer, Paul T Martin
Skeletal Muscle|February 21, 2015
A role for Galgt1 in skeletal muscle regenerationNeha Singhal, Paul T Martin
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Current Opinion in Pharmacology|June 18, 2003
Role of transcription factors in skeletal muscle and the potential for pharmacological manipulationPaul T Martin
Glycobiology|May 9, 2003
Dystroglycan glycosylation and its role in matrix binding in skeletal musclePaul T Martin
Current Molecular Medicine|June 23, 2007
Congenital muscular dystrophies involving the O-mannose pathwayPaul T Martin
Journal of Neurocytology|March 23, 2004
Glycobiology of the neuromuscular junctionPaul T Martin
Glycobiology|February 5, 2002
Glycobiology of the synapsePaul T Martin
Nature Clinical Practice. Neurology|August 26, 2006
Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stagePaul T Martin
Seminars in Pediatric Neurology|April 6, 2006
The dystroglycanopathies: the new disorders of O-linked glycosylationPaul T Martin
Methods in Enzymology|September 7, 2010
Genetic defects in muscular dystrophyKumaran Chandrasekharan, Paul T Martin
Molecular Therapy. Methods & Clinical Development|April 19, 2021
Micro-laminin gene therapy can function as an inhibitor of muscle disease in the dy<sup>W</sup> mouse model of MDC1ADavin Packer, Paul T Martin
Skeletal Muscle|February 21, 2015
A role for Galgt1 in skeletal muscle regenerationNeha Singhal, Paul T Martin
Pageof 8